

## Welireg® (belzutifan) - New indication

- On December 14, 2023, Merck announced the FDA approval of Welireg (belzutifan), for the treatment of adult patients with advanced renal cell carcinoma (RCC) following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI).
- Welireg is also approved for the treatment of adult patients with von Hippel-Lindau (VHL) disease
  who require therapy for associated RCC, central nervous system (CNS) hemangioblastomas, or
  pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery.
- The approval of Welireg for the new indication was based on a LITESPARK-005, an open-label, randomized, active-controlled study in 746 patients with unresectable, locally advanced or metastatic clear cell RCC that progressed following PD-1 or PD-L1 checkpoint inhibitor and VEGF receptor targeted therapies either in sequence or in combination. Patients were randomized to receive Welireg or everolimus. The major efficacy endpoints were progression free survival (PFS) and overall survival (OS). An additional endpoint was objective response rate (ORR).
  - Median PFS was 5.6 months (95% CI: 3.9, 7.0) with Welireg and 5.6 months (95% CI: 4.8, 5.8) with everolimus (hazard ratio 0.75, 95% CI: 0.63, 0.90; p = 0.0008).
  - OS results were immature.
  - The ORR was 22% (95% CI: 18, 27) with Welireg vs. 4% (95% CI: 2, 6) with everolimus (p < 0.0001).</li>
- Welireg carries a boxed warning for embryo-fetal toxicity.
- The most common adverse reactions (≥ 25%), including laboratory abnormalities, with Welireg
  use were decreased hemoglobin, fatigue, musculoskeletal pain, increased creatinine, decreased
  lymphocytes, increased alanine aminotransferase, decreased sodium, increased potassium, and
  increased aspartate aminotransferase.
- The recommended dosage of Welireg for both of its indications is 120 mg administered orally once daily until disease progression or unacceptable toxicity.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.